Conference abstract · 10 Aug 2017
Conference abstractPublished 23 Sep 2013
Commercialization considerations for biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biosimilars have been in the market for years driven by early products such as recombinant insulin and human growth hormone. European approval of biosimilar GCSF and erythropoietin combined with approval for Dr. Reddy?s Reditux has driven the expectation of a large market opportunity for biosimilars. Many companies have entered the space ranging from major international pharmaceutical and biopharmaceutical companies to scores of companies in emerging markets. OSG will outline the market opportunity in both developed and developing/pharmerging markets and highlight key elements required for building a success biosimilar business including; selection of therapeutic areas for development, determining the best customer segments for commercialization, developing robust clinical and regulatory plans, defining the patient experience and ensuring market access. OSG will leverage its unique insights into the decision by physicians, patients and payers to use biosimilars coupled with its team?s 20 year history with biosimilar development and commercialization.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 27 Oct 2014
Biosimilars in emerging markets: Regulatory and commercial considerations
Conference abstract · 4 Apr 2024
Understanding the commercial value of Biosimilars: Learning from launches in EU and US
Conference abstract · 16 Sep 2020
Challenges With Successful Commercialization Of Biosimilars
Editorial · 13 May 2019
Pharma Sci-Commercializing Biosimilars: Challenges, New Strategies and Finding Path to Success- Prashant A Pandya-Reliance Lifesciences
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Steven Lehrer”

